Sciomics: Solving Alzheimers with this company’s new approach?

Home  >>  News  >>  Sciomics: Solving Alzheimers with this company’s new approach?

Sciomics: Solving Alzheimers with this company’s new approach?

On March 14, 2018, Posted by , In News, By , , With Comments Off on Sciomics: Solving Alzheimers with this company’s new approach? media recently profiled our member Sciomics, a German Cancer Research Center (DKFZ) spin-off founded in 2013 by a team of researchers led by Dr. Christoph Schröder and Dr. Jörg Hoheisel. Sciomics has developed antibody microarrays as a tool for analyzing complex protein samples. Using their expertise, they are able to address the complete workflow of sample analysis with both standardized and customized arrays.

Testing viles for assays_Alzheimers

In a joint project of academic and business partners, a set of more than a thousand antibodies has been collected. It allows for sensitive protein detection from a broad range of animal and human samples, including plasma, serum, CSF, tissue, cells, and interstitial fluids.

Dr. Ronny Schmidt, Head of Business Development presents the concept: “Genetic information alone has not provided sufficient insight on neurodegenerative diseases. We need to look at information on protein expression levels and post-translational modifications—and monitor changes over time.”

Armed with this high protein expression profiling technology, it is now possible to identify a diagnostic biomarker and its corresponding therapeutic target in parallel, integrating biomarker discovery and validation into the drug development process and facilitating companion diagnostics.

The Sciomics immunoassay-based approach enables applying sufficient throughput in the early phase of biomarker detection, a process dominated by mass spectrometry (MS) methods. Although MS provides a higher level of information detail, the need for expensive instrumentation and technological and bioinformatics knowledge prevents its use in the later biomarker validation and clinical application phases, where immunoassays are the standard method.

Ubiquitination studies are especially insightful not only for studying neurodegenerative diseases, such as Alzheimer’s disease, but also immune disorders, immuno-oncology, aging, and regenerative medicine. So it is no surprise that after addressing phosphorylation as the most common PTM, the Sciomics development team now sets their focus on ubiquitination.

ScioUbi, a novel immunoarray developed for analyzing the ubiquitination status of over a thousand proteins, will officially be presented at the Analytica laboratory trade fair in Munich in April 2018.

Read the original and complete press release here.

Related Post

Comments are closed.